Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Christian Tuxen"'
Autor:
Lars Køber, Morten Schou, Kasper Karmark Iversen, Dan Eik Høfsten, Finn Gustafsson, Brian Bridal Løgstrup, Olav W Nielsen, Kasper Rossing, Signe Glargaard, Jakob Hartvig Thomsen, Christian Tuxen, Christian Axel Bang, Matias Greve Lindholm, Ekim Seven, Anders Barasa, Nis Stride, Søren Vraa, Marlene Tofterup, Rasmus Vedby Rasmussen, Jens Jakob Thune
Publikováno v:
BMJ Open, Vol 14, Iss 1 (2024)
Introduction Pleural effusion is present in half of the patients hospitalised with acute heart failure. The condition is treated with diuretics and/or therapeutic thoracentesis for larger effusions. No evidence from randomised trials or guidelines su
Externí odkaz:
https://doaj.org/article/3a0c7f501ed04e7796f4823d3efa653f
Autor:
Massar Omar, Jesper Jensen, Caroline Kistorp, Kurt Højlund, Lars Videbæk, Christian Tuxen, Julie H. Larsen, Camilla F. Andersen, Finn Gustafsson, Lars Køber, Morten Schou, Jacob Eifer Møller
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Plasma growth differentiation factor-15 (GDF-15) biomarker levels increase in response to inflammation and tissue injury, and increased levels of GDF-15 are associated with increased risk of mortality in patients with heart failur
Externí odkaz:
https://doaj.org/article/655ef519868a42d5b17b7fd6d353a298
Autor:
Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kjær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Emil Fosbøl, Niels Eske Bruun, Lars Videbæk, Peter Hartmund Frederiksen, Jacob Eifer Møller, Morten Schou
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-8 (2019)
Abstract Background Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong life in patients withou
Externí odkaz:
https://doaj.org/article/ad3c51a319e64b70b6d87060f5ff0ba8
Publikováno v:
Diagnostics, Vol 1, Iss 1, Pp 38-52 (2011)
Objective: Intensive medical treatment of heart failure (HF) patients with diabetes may reduce the endothelial dysfunction and the accelerated atherosclerotic process seen in these patients. To study this, we investigated the endothelial function and
Externí odkaz:
https://doaj.org/article/ac408a60f91c44789f5586217586d02c
Autor:
Camilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, Daniel El Fassi, Holger J. Møller, Jørgen A. Lindholm Kurtzhals, Bjarne Styrishave, Caroline Kistorp, Christian Tuxen, Mikael K. Poulsen, Jens Faber, Lars Køber, Finn Gustafsson, Jacob E. Møller, Morten Schou, Jesper Jensen
Publikováno v:
Fuchs Andersen, C, Omar, M, Glenthøj, A, El Fassi, D, Møller, H J, Lindholm Kurtzhals, J A, Styrishave, B, Kistorp, C, Tuxen, C, Poulsen, M K, Faber, J, Køber, L, Gustafsson, F, Møller, J E, Schou, M & Jensen, J 2023, ' Effects of empagliflozin on erythropoiesis in heart failure : data from the Empire HF trial ', European Journal of Heart Failure, vol. 25, no. 2, pp. 226-234 . https://doi.org/10.1002/ejhf.2735
Aims: It remains unknown whether the consistently observed increase in haematocrit with sodium–glucose cotransporter 2 inhibitors is caused by diuresis-associated haemoconcentration or increased erythropoiesis. We aimed to investigate the early eff
Autor:
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Mikael Kjær Poulsen, Jens Faber, Lars Køber, Finn Gustafsson, Jacob Eifer Møller, Morten Schou
Publikováno v:
Circulation: Heart Failure. 15
Autor:
Jens Faber, Jesper Jensen, Mariam Elmegaard Malik, Christian Tuxen, Lars Thorbjørn Jensen, Lars Køber, Niels Eske Bruun, Morten Schou, Ida Gustafsson, Emil L. Fosbøl, Finn Gustafsson, Caroline Kistorp, Julie Lyng Forman, Massar Omar, Jacob E. Møller
Publikováno v:
Jensen, J, Omar, M, Kistorp, C, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Faber, J, Malik, M E, Fosbøl, E L, Bruun, N E, Forman, J L, Jensen, L T, Møller, J E & Schou, M 2021, ' Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal) : a prespecified substudy of a double-blind, randomised, placebo-controlled trial ', The Lancet Diabetes & Endocrinology, vol. 9, no. 2, pp. 106-116 . https://doi.org/10.1016/S2213-8587(20)30382-X
Jensen, J, Omar, M, Kistorp, C, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Faber, J, Malik, M E, Fosbøl, E L, Bruun, N E, Forman, J L, Jensen, L T, Møller, J E & Schou, M 2021, ' Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal) : a prespecified substudy of a double-blind, randomised, placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 2, pp. 106-116 . https://doi.org/10.1016/S2213-8587(20)30382-X
Jensen, J, Omar, M, Kistorp, C, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Faber, J, Malik, M E, Fosbøl, E L, Bruun, N E, Forman, J L, Jensen, L T, Møller, J E & Schou, M 2021, ' Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal) : a prespecified substudy of a double-blind, randomised, placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 2, pp. 106-116 . https://doi.org/10.1016/S2213-8587(20)30382-X
BACKGROUND: SGLT2 inhibitors are a promising treatment option in patients with heart failure and reduced ejection fraction. We aimed to investigate the effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured
Autor:
Massar Omar, Jesper Jensen, Caroline Kistorp, Kurt Højlund, Lars Videbæk, Christian Tuxen, Julie H. Larsen, Camilla F. Andersen, Finn Gustafsson, Lars Køber, Morten Schou, Jacob Eifer Møller
Publikováno v:
Omar, M, Jensen, J, Kistorp, C, Højlund, K, Videbæk, L, Tuxen, C, Larsen, J H, Andersen, C F, Gustafsson, F, Køber, L, Schou, M & Møller, J E 2022, ' The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure : a randomized controlled trial (Empire HF Biomarker) ', Cardiovascular Diabetology, vol. 21, 34 . https://doi.org/10.1186/s12933-022-01463-2
Omar, M, Jensen, J, Kistorp, C, Højlund, K, Videbæk, L, Tuxen, C, Larsen, J H, Andersen, C F, Gustafsson, F, Køber, L, Schou, M & Møller, J E 2022, ' The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure : a randomized controlled trial (Empire HF Biomarker) ', Cardiovascular Diabetology, vol. 21, no. 1, 34 . https://doi.org/10.1186/s12933-022-01463-2
Omar, M, Jensen, J, Kistorp, C, Højlund, K, Videbæk, L, Tuxen, C, Larsen, J H, Andersen, C F, Gustafsson, F, Køber, L, Schou, M & Møller, J E 2022, ' The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure : a randomized controlled trial (Empire HF Biomarker) ', Cardiovascular Diabetology, vol. 21, no. 1, 34 . https://doi.org/10.1186/s12933-022-01463-2
Background Plasma growth differentiation factor-15 (GDF-15) biomarker levels increase in response to inflammation and tissue injury, and increased levels of GDF-15 are associated with increased risk of mortality in patients with heart failure with re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b6a6412bbe3d1e4c11f80b5b70b561
https://findresearcher.sdu.dk:8443/ws/files/199867422/s12933_022_01463_2_1_.pdf
https://findresearcher.sdu.dk:8443/ws/files/199867422/s12933_022_01463_2_1_.pdf
Autor:
Emil L. Fosbøl, Thomas Sehestedt, Christian Tuxen, Nana Valeur Køber, Christian Torp-Pedersen, Lars Køber, Jawad H. Butt, Eva Havers-Borgersen, Gunnar Gislason, Nis Høst, Jeppe Kofoed Petersen, Lauge Østergaard, Andreas Dalsgaard Jensen, Lars Søndergaard
Publikováno v:
JACC: Cardiovascular Interventions. 14:1503-1505
Autor:
Jesper Jensen, Massar Omar, Mulham Ali, Peter H. Frederiksen, Caroline Kistorp, Christian Tuxen, Camilla F. Andersen, Julie H. Larsen, Mads Kristian Ersbøll, Lars Køber, Finn Gustafsson, Jens Faber, Julie Lyng Forman, Jacob Eifer Møller, Morten Schou
Publikováno v:
Jensen, J, Omar, M, Ali, M, Frederiksen, P H, Kistorp, C, Tuxen, C, Andersen, C F, Larsen, J H, Ersbøll, M K, Køber, L, Gustafsson, F, Faber, J, Forman, J L, Møller, J E & Schou, M 2022, ' The effect of empagliflozin on contractile reserve in heart failure : Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial ', American Heart Journal, vol. 250, pp. 57-65 . https://doi.org/10.1016/j.ahj.2022.04.008
Background: Sodium-glucose co-transporter-2 inhibitors improve cardiac structure but most studies suggest no change in left ventricular (LV) systolic function at rest. Whether sodium-glucose co-transporter-2 inhibitors improve LV contractile reserve